Chakshu Research Inc.
This article was originally published in Start Up
Executive Summary
Chakshu Research believes its drug candidate can interfere with the pathogenic processes that cause oxidative stress, which can, in turn, cause tissue damage. The company is developing a solution, made up of GRAS substances, designed to reduce the amount of reactive metal ions that act as a catalyst of harmful oxidative reactions in the eye, and thus treat cataracts and other ophthalmic disorders.
You may also be interested in...
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Targeted Cancer Therapeutics," features profiles of Coronado Biosciences, Emiliem and SynDevRx. Plus these Start-Ups Across Health Care: Activaero, Chakshu Research, Myomo and Valor Medical.
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Targeted Cancer Therapeutics," features profiles of Coronado Biosciences, Emiliem and SynDevRx. Plus these Start-Ups Across Health Care: Activaero, Chakshu Research, Myomo and Valor Medical.
Optical Illusion: Why Genentech Is Winning the Fight Over Lucentis
With Lucentis sales slumping, Genentech took the bold step of cutting off ophthalmologists from supply of Avastin, further angering providers already seething about the company's maneuvering around an NIH-funded comparative trial. The desperate move of a company painted into a corner? Hardly. Beneath the headlines, it looks like Genentech is going to win the fight to prevent Avastin from becoming standard care for AMD.